Alzheimer Disease
Conditions
Keywords
Alzheimer Disease, Transcranial Magnetic Stimulation, Extracorporeal Shockwave Therapy
Brief summary
This is a randomized, double-blind, placebo-controlled clinical trial; that will evaluate the effectiveness of the use of transcranial pulse stimulation in people living with Alzheimer's disease, coming from the Institute of Psychiatry (IPQ) of the Hospital das Clinicas, Faculty of Medicine, University of São Paulo, and the Institute of Physical Medicine and Rehabilitation (IMREA) at the Hospital das Clínicas, Faculty of Medicine, University of São Paulo. Participants will be classified according to the stage of Alzheimer's disease, determined by a psychiatrist and neuropsychologists. A total of 50 volunteers will be randomized blindly. In addition to evaluating the clinical course and imaging examination, the use of scales that assess functional and cognitive disability will be used for the recruitment of volunteers. Volunteers will be randomized into two study groups, and will receive the intervention that will consist of ten sessions, held twice a week. The Storz Neurolith™ equipment (Storz Medical, Tagerwillen, Switzerland) will be used to administer transcranial pulse stimulation.
Interventions
Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
Sponsors
University of Sao Paulo General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Masking description
Double (Care Provider, Outcomes Assessor)
Intervention model description
Parallel Assignment
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Individuals who have Alzheimer's disease will be selected; * Are aged ≥50 years; * Medical assistance provided by the psychiatry service at IPQ; * Who agree to participate after consent via the Informed Consent Term .
Exclusion criteria
* Make regular use of anticoagulants; * Has skullcap failure, craniectomy without cranioplasty; * Have a diagnosis of brain neoplasms or any type of nodule in the brain region; * Have recent brain bleeds or a diagnosis of cerebral arteriovenous malformation; * Be diagnosed with a type of dementia other than Alzheimer's; * Have Mild Cognitive Impairment of the Elderly (MCI); * Have clinical changes that put the test at risk, such as severe cardiorespiratory disorders; * Has a severe cognitive disorder that makes it impossible to apply therapy or questionnaires; * It is clinically or socially impossible for the patient to attend IMREA for applications twice a week during the study period; * Those who disagree to participate after consent via the Informed Consent Term .
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive Functions | Baseline and up to one, three, six and twelve months from intervention | Cognitive functions, using Alzheimer's Disease Assessment Scale (ADAS-Cog) |
Countries
Brazil
Contacts
Primary ContactMarta Imamura, MD PhD
Backup ContactArtur Santos
Outcome results
None listed